{"result": "(\"entity\"<|>NAVB<|>ORGANIZATION<|>NAVB is an organization involved in dietary management and treatment protocols for phenylketonuria (PKU).)\n##\n(\"entity\"<|>PHENYLKETONURIA<|>EVENT<|>Phenylketonuria (PKU) is a metabolic disorder that requires strict dietary management to prevent complications during pregnancy and throughout life.)\n##\n(\"entity\"<|>SAPROPTERINA<|>ORGANIZATION<|>Sapropterina is a commercial preparation used in the treatment of PKU, which helps increase tolerance to phenylalanine (Phe).)\n##\n(\"entity\"<|>GLUCOMACROPEPTIDE<|>ORGANIZATION<|>Glucomacropeptide (GMP) is a dairy-derived peptide that is low in phenylalanine and is used to improve dietary options for PKU patients.)\n##\n(\"entity\"<|>AMINOÁCIDOS NEUTROS<|>ORGANIZATION<|>Neutral amino acids (LNAA) are used in PKU treatment to compete with phenylalanine for transport across the blood-brain barrier.)\n##\n(\"entity\"<|>PHE<|>PERSON<|>Phe refers to phenylalanine, an amino acid that must be carefully managed in individuals with PKU.)\n##\n(\"relationship\"<|>NAVB<|>PHENYLKETONURIA<|>NAVB is involved in the dietary management and treatment protocols for individuals with phenylketonuria (PKU).<|>8)\n##\n(\"relationship\"<|>SAPROPTERINA<|>PHENYLKETONURIA<|>Sapropterina is used to treat phenylketonuria by increasing tolerance to phenylalanine.<|>7)\n##\n(\"relationship\"<|>GLUCOMACROPEPTIDE<|>PHENYLKETONURIA<|>Glucomacropeptide provides dietary options for individuals with phenylketonuria, helping to manage their condition.<|>6)\n##\n(\"relationship\"<|>AMINOÁCIDOS NEUTROS<|>PHENYLKETONURIA<|>Neutral amino acids are used in the treatment of phenylketonuria to reduce phenylalanine levels in the brain.<|>7)\n##\n(\"relationship\"<|>PHE<|>PHENYLKETONURIA<|>Phenylalanine (Phe) is the amino acid that individuals with phenylketonuria must manage carefully to avoid health complications.<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: NAVB (a la mitad si el proceso intercurrente es leve o por completo si es grave)\nb. Mantener el suplemento libre de proteínas para promover la síntesis proteica.\nc. Aumentar la ingesta de energía añadiendo polímeros de glucosa a los líquidos, incluyendo la fórmula libre de Phe (tabla 6).\nd. Ofrecer abundantes líquidos y no forzar la alimentación.\n\n2.5. Fenilcetonuria en la embarazada\n\nEs necesario un control estricto de las cifras de Phe tanto en el período preconcepcional como durante todo el embarazo, con el fin de evitar o prevenir la embriopatía por PKU materna (retraso del crecimiento, microcefalia, cardiopatía congénita). Por ello:\n\na. Debe iniciarse la dieta en las 10 semanas antes del embarazo.\nb. Inicialmente se puede calcular una ingesta de 6 mg/kg/día de PNAVB, la cual se deberá aumentar según la tolerancia individual en el segundo y tercer trimestre del embarazo (está comprobado que a partir de ese momento existe un aumento\n---\n## BLOQUE: PROTEÍNAS Y AMINOÁCIDOS\n\npor parte del hígado fetal de la capacidad para metabolizar la Phe de la madre).\n\nc. Se debe procurar mantener las cifras de Phe por debajo de 4 mg/dl (240 μmol/l).\nd. Debe valorarse la suplementación con tirosina (100 mg/kg/día) durante el segundo-tercer trimestre, así como valorar posible déficit de carnitina, L-PUFA o micronutrientes5.\n\n### 2.6. Nuevas terapias\n\nLas limitaciones del tratamiento actual (dieta de por vida muy restringida, efectos secundarios de una dieta de restricción proteica prolongada, posible afectación ósea a pesar de la dieta y el desacoplamiento a la dieta que puede generar ciertos trastornos neurológicos e incluso enfermedades neurodegenerativas en el adulto) han hecho que en la actualidad se barajen otras posibilidades terapéuticas en el manejo de la PKU.\n\n#### 2.6.1. Coenzima tetrahidrobipterina\n\nLa BH4 es cofactor de PAH y se ha comprobado que aumenta la tolerancia a la Phe, lo que permite liberalizar la dieta, haciendo en algunos casos innecesaria la fórmula especial.\n\nExisten estudios que permiten correlacionar la mutación genética con la respuesta a BH46, 7. En la actualidad, la selección de pacientes con respuesta a BH4 se realiza mediante la realización de prueba de sobrecarga de BH4 (20 mg/kg), considerándose como buena respuesta si los valores de Phe en plasma disminuyen igual o más del 30% del valor basal de Phe.\n\nExisten diferentes modalidades de prueba de sobrecarga de BH4 (24 horas, 48 horas, 1 mes, etc.).\n\nEn la actualidad existe un preparado comercial, Sapropterina (comprimidos 100 mg de administración vía oral) y se han descrito pocos efectos secundarios (cefalea, rinorrea, molestias abdominales).\n\n#### 2.6.2. Glucomacropéptido (GMP)\n\nEs un péptido grande obtenido en la industria láctea a partir de la caseína que contiene cantidades muy pequeñas de fenilalanina (2 mg/g). El preparado comercial se obtiene a partir del queso, mejora el sabor y la variedad de la dieta para PKU y está suplementado con arginina, histidina, leucina, tirosina y triptófano para complementar el aporte proteico11, 12. Los productos más destacados son: harina, chocolate, puding, bebidas deportivas, snacks.\n\nLos GMP poseen otras propiedades como que presentan una buena termoestabilidad y una adecuada solubilidad en ácidos. Otras de las propiedades de los GMP son que podrían descender tanto la fenilalanina plasmática como la cerebral y que disminuyen la sensación de hambre a través de un descenso de la GHrelina8.\n\n#### 2.6.3. Aminoácidos neutros (LNAA)\n\nLos LNAA son arginina, histidina, isoleucina, leucina, lisina, metionina, treonina, triptófano, tirosina y valina. Estos compiten con la Phe por los transportadores específicos para atravesar la barrera hematoencefálica y la mucosa intestinal, utilizando mecanismo de inhibición competitiva. Si aumentamos el aporte de LNAA, disminuye el paso de Phe al cerebro.\n\nEsta opción terapéutica es más eficaz en aquellos pacientes con mala adherencia a la dieta10, 12.\n\nEs necesario investigar sobre la composición óptima de LNAA, efectos secundarios a largo plazo y beneficio a largo plazo en PKU.\n\nLa dosis en adultos es de 18 g/día. Útil en adultos y ancian\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}